Stock listing
Stockholm:INIT Initiator Pharma A/S Aktie
Follow Initiator Pharma A/S into a list and get an email when it puts out news.
Share price · OMXSTO:INIT
2.50 SEK -0.07 (-2.7%)
Close on Nov 20, 2026
- Day range
- 2.46 – 2.62 SEKNov 20, 2026
- Volume
- 50,477 sharesNov 20, 2026
- Market cap
- 171.1M SEKAt the close on Nov 20, 2026 · price × 68.45M shares outstanding
- 52-week range
- 1.67 – 3.65 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 364,131 SEKMedian day 123,064 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXSTO:INIT · SEK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 2.50 | -0.07 | -2.7% | 2.47 | 2.62 | 2.46 | 50,477 | |
| 2.57 | +0.16 | +6.6% | 2.41 | 2.64 | 2.39 | 1,401,672 | |
| 2.41 | -0.28 | -10.4% | 2.69 | 2.69 | 2.41 | 218,457 | |
| 2.69 | +0.42 | +18.5% | 2.35 | 2.80 | 2.27 | 154,910 | |
| 2.27 | -0.03 | -1.3% | 2.38 | 2.42 | 2.22 | 250,551 | |
| 2.30 | -0.19 | -7.6% | 2.59 | 2.59 | 2.28 | 159,757 | |
| 2.49 | +0.31 | +14.2% | 2.51 | 2.54 | 2.40 | 129,930 | |
| 2.18 | +0.03 | +1.4% | 2.19 | 2.49 | 2.10 | 211,412 | |
| 2.15 | +0.18 | +9.1% | 1.95 | 2.27 | 1.865 | 198,526 | |
| 1.97 | +0.165 | +9.1% | 1.81 | 1.975 | 1.81 | 50,656 | |
| 1.805 | -0.005 | -0.3% | 1.855 | 1.985 | 1.755 | 110,350 | |
| 1.81 | -0.135 | -6.9% | 1.915 | 1.915 | 1.81 | 96,523 | |
| 1.945 | -0.145 | -6.9% | 1.99 | 1.995 | 1.885 | 46,235 | |
| 2.09 | +0.04 | +2.0% | 2.01 | 2.29 | 1.875 | 258,490 | |
| 2.05 | -0.12 | -5.5% | 2.17 | 2.22 | 1.715 | 802,710 | |
| 2.17 | -0.07 | -3.1% | 2.24 | 2.32 | 2.10 | 47,337 | |
| 2.24 | -0.13 | -5.5% | 2.33 | 2.36 | 2.19 | 126,103 | |
| 2.37 | +0.13 | +5.8% | 2.38 | 2.49 | 2.24 | 64,308 | |
| 2.24 | 0.00 | 0.0% | 2.29 | 2.29 | 2.15 | 42,060 | |
| 2.24 | -0.08 | -3.4% | 2.21 | 2.38 | 2.20 | 66,084 | |
| 2.32 | +0.02 | +0.9% | 2.24 | 2.32 | 2.16 | 85,473 | |
| 2.30 | +0.21 | +10.0% | 2.20 | 2.30 | 2.13 | 149,330 | |
| 2.09 | +0.03 | +1.5% | 1.905 | 2.09 | 1.905 | 58,941 | |
| 2.06 | +0.065 | +3.3% | 2.08 | 2.20 | 1.925 | 159,439 | |
| 1.995 | -0.145 | -6.8% | 2.23 | 2.23 | 1.925 | 183,755 | |
| 2.14 | +0.145 | +7.3% | 2.10 | 2.16 | 2.05 | 120,389 | |
| 1.995 | +0.195 | +10.8% | 1.85 | 1.995 | 1.85 | 98,019 | |
| 1.80 | +0.03 | +1.7% | 1.77 | 1.895 | 1.77 | 29,987 | |
| 1.77 | +0.025 | +1.4% | 1.725 | 1.77 | 1.665 | 95,479 | |
| 1.745 | -0.12 | -6.4% | 1.895 | 1.895 | 1.705 | 156,097 | |
| 1.865 | -0.10 | -5.1% | 1.915 | 1.96 | 1.835 | 179,079 | |
| 1.965 | -0.065 | -3.2% | 1.99 | 2.05 | 1.915 | 64,900 | |
| 2.03 | +0.03 | +1.5% | 1.995 | 2.06 | 1.96 | 14,528 | |
| 2.00 | -0.12 | -5.7% | 2.11 | 2.11 | 1.97 | 228,592 | |
| 2.12 | +0.10 | +5.0% | 1.98 | 2.30 | 1.815 | 410,646 | |
| 2.02 | -0.01 | -0.5% | 2.01 | 2.08 | 1.98 | 216,879 | |
| 2.03 | -0.05 | -2.4% | 2.14 | 2.14 | 1.965 | 219,118 | |
| 2.08 | -0.06 | -2.8% | 2.13 | 2.24 | 2.07 | 138,983 | |
| 2.14 | +0.09 | +4.4% | 2.15 | 2.15 | 2.01 | 99,923 | |
| 2.05 | -0.11 | -5.1% | 2.23 | 2.23 | 1.975 | 146,260 | |
| 2.16 | -0.03 | -1.4% | 2.18 | 2.24 | 2.10 | 287,956 | |
| 2.19 | +0.08 | +3.8% | 2.09 | 2.25 | 2.08 | 209,462 | |
| 2.11 | -0.07 | -3.2% | 2.22 | 2.22 | 2.06 | 284,706 | |
| 2.18 | -0.06 | -2.7% | 2.24 | 2.29 | 2.11 | 261,474 | |
| 2.24 | -0.05 | -2.2% | 2.24 | 2.33 | 2.15 | 233,114 | |
| 2.29 | -0.06 | -2.6% | 2.36 | 2.37 | 2.25 | 87,219 | |
| 2.35 | -0.09 | -3.7% | 2.42 | 2.45 | 2.33 | 55,363 | |
| 2.44 | +0.05 | +2.1% | 2.33 | 2.44 | 2.33 | 21,211 | |
| 2.39 | +0.01 | +0.4% | 2.38 | 2.48 | 2.32 | 51,280 | |
| 2.38 | -0.10 | -4.0% | 2.43 | 2.45 | 2.32 | 125,738 | |
| 2.48 | +0.09 | +3.8% | 2.37 | 2.48 | 2.34 | 46,420 | |
| 2.39 | 0.00 | 0.0% | 2.35 | 2.54 | 2.35 | 112,276 | |
| 2.39 | +0.05 | +2.1% | 2.32 | 2.41 | 2.29 | 77,812 | |
| 2.34 | -0.01 | -0.4% | 2.41 | 2.41 | 2.29 | 70,948 | |
| 2.35 | +0.04 | +1.7% | 2.33 | 2.40 | 2.32 | 73,826 | |
| 2.31 | -0.03 | -1.3% | 2.26 | 2.34 | 2.26 | 34,140 | |
| 2.34 | +0.04 | +1.7% | 2.30 | 2.34 | 2.24 | 108,494 | |
| 2.30 | -0.05 | -2.1% | 2.55 | 2.55 | 2.27 | 185,689 | |
| 2.35 | -0.08 | -3.3% | 2.43 | 2.43 | 2.34 | 23,631 | |
| 2.43 | -0.04 | -1.6% | 2.48 | 2.48 | 2.34 | 155,973 | |
| 2.47 | -0.03 | -1.2% | 2.50 | 2.50 | 2.39 | 146,682 | |
| 2.50 | -0.09 | -3.5% | 2.50 | 2.66 | 2.42 | 99,903 | |
| 2.59 | +0.06 | +2.4% | 2.54 | 2.67 | 2.40 | 265,306 | |
| 2.53 | 0.00 | 0.0% | 2.64 | 2.65 | 2.37 | 64,652 |
- Ticker
- Stockholm:INIT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Stockholm
- Currency
- SEK
What changed lately
Latest news release · Sep 14, 2026
Initiator Pharma strengthens its management team – appoints Annette Säfholm as COO
Latest news
Initiator Pharma strengthens its management team – appoints Annette Säfholm as COO
Sep 14, 2026
Closed 2.35 (-3.7%) on Sep 14, 2026
Initiator Pharma secures two European patents for pudafensine
Aug 19, 2026
Closed 2.53 (+2.0%) on Aug 19, 2026
Initiator Pharma attends BIO 2026 in San Diego
Jun 23, 2026
Closed 2.78 (+4.9%) on Jun 23, 2026
Initiator Pharma A/S – Resolutions of the annual general meeting 2026
May 29, 2026
Closed 2.99 (+3.1%) on May 29, 2026
Initiator Pharma A/S calls for the Annual General Meeting
May 12, 2026
Closed 3.00 (-5.7%) on May 12, 2026
Initiator Pharma Q1 2026 Operating Loss DKK 11.4 Mln
May 8, 2026
Closed 3.36 (-0.3%) on May 8, 2026
Initiator Pharma progresses patient enrollment in Phase 2a vulvodynia study
Apr 28, 2026
Closed 3.35 (+3.4%) on Apr 29, 2026
Initiator Pharma: Full focus on pudafensine, IP2018 is discontinued
Apr 21, 2026
Closed 3.24 (0.0%) on Apr 21, 2026
Initiator Pharma To Fully Prioritize Pudafensine
Apr 17, 2026
Closed 3.19 (-5.9%) on Apr 17, 2026
Initiator Pharma to present at Redeye Healthcare Day 2026
Apr 10, 2026
Closed 3.27 (+1.6%) on Apr 10, 2026
Initiator Pharma A/S on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 15 in the last 12 months · 25 in all · newest Sep 14, 2026 · oldest 2024
Valuation
Price/book 13.4× against a median of 0.9×: 8th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- 160.0M SEK
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 13.4×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 1.1×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Initiator Pharma A/S · OMXSTO:INIT | US$16.74M | US$15.65M | n/a | n/a | n/a | 13.4× | n/a | 1.1× | n/a |
| Resverlogix Corp. · TSX:RVX | US$18.01M | US$95.55M | n/a | n/a | n/a | n/a | n/a | n/a | 0.26 |
| SynCore Biotechnology Co., Ltd. · TPEX:4192 | US$16.80M | US$12.38M | n/a | 15.6× | n/a | 2.5× | −178.5% | 0.0× | n/a |
| Neurotech International Ltd. · ASX:NTI | US$16.63M | US$15.06M | n/a | n/a | n/a | 41.1× | n/a | 0.0× | n/a |
| Akari Therapeutics PLC · NASDAQ:AKTX | US$16.41M | US$10.66M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.49 |
| Lipocine Inc. · NASDAQ:LPCN | US$16.39M | −US$5.07M | n/a | −1.4× | n/a | 0.8× | −249.2% | 0.0× | 1.18 |
| MaaT Pharma · EURONEXT:MAAT | US$16.11M | US$23.36M | n/a | 4.7× | n/a | n/a | −686.6% | n/a | n/a |
| Elicera Therapeutics AB · OMXSTO:ELIC | US$16.09M | US$10.40M | n/a | n/a | n/a | 2.9× | n/a | 0.0× | n/a |
| Pasithea Therapeutics Corp. · NASDAQ:KTTA | US$16.00M | −US$25.22M | n/a | n/a | −0.1× | 0.4× | n/a | 0.0× | 0.97 |
| Atossa Therapeutics, Inc. · NASDAQ:ATOS | US$15.92M | −US$4.66M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 0.87 |
| Quoin Pharmaceuticals. Ltd · NASDAQ:QNRX | US$15.76M | −US$17.43M | n/a | n/a | n/a | 0.6× | n/a | 0.0× | 0.68 |
| Median of the others | US$16.25M | US$10.53M | 4.7× | −0.1× | 0.9× | −249.2% | 0.0× | 0.92 |
Forecasts
Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 5.11 SEK · Analysts' mean
- EPS, year to Dec 2026
- -0.59 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Claus Elsborg Olesen | CEO and board member |
| Annette Säfholm | Chief Operating Business Officer (COO) |
Board
| Director | Role |
|---|---|
| Magnus Persson | Chairman of the Board |
| Annette Colin | Board member |
| Christina Lloyd | Board member |
| Claus Elsborg Olesen | CEO and board member |
| Gunilla Ekström | Board member |
| Peter Holm | Board member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2025 | Feb 20, 2026 · Before open | −3.9% |
| Q3 2025 | Nov 21, 2025 · Before open | +1.8% |
| Q2 2025 | Aug 22, 2025 · Before open | +4.3% |
| Q1 2025 | May 9, 2025 · Before open | −4.7% |
| Q4 2024 | Feb 28, 2025 · Before open | 0.0% |
| Q3 2024 | Nov 29, 2024 · Before open | +3.5% |
| Q2 2024 | Aug 23, 2024 · Before open | 0.0% |
| Q1 2024 | May 10, 2024 · Before open | −0.7% |
| Q4 2023 | Feb 23, 2024 · Before open | +0.9% |
| Q3 2023 | Nov 10, 2023 · Before open | +2.9% |
All 17 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2023 | Aug 25, 2023 · Before open | +1.4% |
| Q1 2023 | May 5, 2023 · Before open | +2.2% |
| Q4 2022 | Feb 17, 2023 · Before open | +0.3% |
| Q3 2022 | Nov 4, 2022 · Before open | −4.4% |
| Q2 2022 | Aug 26, 2022 · Before open | −0.3% |
| Q1 2022 | May 6, 2022 · Before open | 0.0% |
| Q4 2021 | Feb 18, 2022 · Before open | −5.7% |
Financials
Annual, in DKK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Cost of revenue | 14.8M | 11.1K | 23.4K | 38.4K | 21.6K | 9.30K | 8.37K | 11.4K | 8.18K | 1.05K |
| Gross profit | -14.8M | -11.1K | -23.4K | -38.4M | -21.6K | -9.30K | -8.37K | -11.4K | -8.18K | -1.05K |
| Research and development | 4.19M | 1.78K | 15.3K | 26.3K | 11.8K | 5.19K | 6.26K | 8.67K | 6.09K | |
| Selling, general and administrative | 2.95M | 3.43M | 3.62M | 3.31M | 1.44M | |||||
| Operating income | -18.2M | -14.5K | -27.0K | -41.7M | -23.1K | -10.5K | -9.34K | -12.6K | -9.56K | -1.33K |
| Depreciation and amortization | 2 | 1 | 11 | 11.0K | 26.0K | 87.0K | 88.0K | 84.0K | 12.0K | |
| EBITDA | -14.5K | -27.0K | -41.7M | -12.1K | 15.5K | 77.7K | 75.4K | 74.4K | 10.7K | |
| Interest expense | 0 | 2.00K | 3.71M | 2.39M | 1.17M | 291.0K | 636.0K | 93.0K | 801.0K | 5.00K |
| Income before tax | -17.1M | -14.8K | -27.7K | -44.1M | -24.2K | -10.2K | -9.97K | -12.7K | -10.4K | -1.34K |
| Income tax | -3.08M | -1.90K | -4.83K | -5.68M | -3.18K | -1.54K | -1.69M | -2.41M | -1.78M | 12.0K |
| Net income | -14.0M | -12.9K | -22.9K | -38.5M | -21.1M | -8.70M | -8.29M | -10.3M | -8.58M | -892.0K |
| Earnings per share, basic | -0.22 | -0.23 | -0.00 | -795.76 | -600.32 | -317.70 | -341.89 | -512.82 | -1,044.17 | -0.08 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 26.3M | 13.4M | 24.1M | 38.9M | 34.1M | 13.5M | 7.36M | 14.3M | 6.97M | 167.0K |
| Short-term investments | 200.0K | |||||||||
| Receivables | 3.33M | 599.0K | 1.71M | 945.0K | 545.0K | 2.97M | 2.71M | 1.92M | ||
| Current assets | 33.0M | 15.3M | 29.8M | 48.3M | 53.7M | 15.6M | 11.4M | 17.2M | 9.09M | 398.0K |
| Property, plant and equipment | 4.00K | 69.0K | 134.0K | |||||||
| Total assets | 33.0M | 15.3M | 29.8M | 48.3M | 53.7M | 15.6M | 11.4M | 17.3M | 9.30M | 563.0K |
| Accounts payable | 864.4K | 366.0K | 407.0K | 801.0K | 4.80M | 666.0K | 1.14M | 239.0K | 1.42M | |
| Current liabilities | 1.28M | 510.0K | 3.19M | 1.75M | 5.42M | 1.19M | 1.53M | 758.0K | 3.33M | 934.0K |
| Long-term debt | 2.15M | 0 | 15.4M | 12.6M | 13.3M | 0 | ||||
| Total debt | 2.15M | 15.4M | 12.6M | 13.3M | ||||||
| Total liabilities | 3.43M | 510.0K | 18.6M | 14.3M | 18.7M | 1.19M | 1.53M | 758.0K | 3.33M | 934.0K |
| Shareholders' equity | 29.6M | 14.8M | 11.2M | 34.0M | 35.0M | 14.4M | 9.91M | 16.6M | 5.96M | -371.0K |
| Shares outstanding | 62.3M | 57.3K | 52.4M | 48.3K | 35.1K | 27.4K | 24.2K | 20.1K | 8.22K | 11.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -18.2M | -12.1M | -17.6M | -32.7M | -34.1M | -8.06M | -8.55M | -13.6M | -7.78M | -178.0K |
| Capital spending | -18.2M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -132.0K | -177.0K |
| Free cash flow | -17.7M | -12.1M | -17.6M | -32.7M | -34.1M | -8.06M | -8.55M | -13.6M | -7.92M | -355.0K |
| Cash from investing | -17.0K | -17.0K | -17.0K | -17.0K | -132.0K | -177.0K | ||||
| Cash from financing | 31.4M | 1.11M | 2.87M | 37.5M | 54.9M | 14.0M | 1.63M | 20.9M | 14.9M | 521.0K |
| Share buybacks | 0 | -690.0K | 0 | |||||||
| Change in cash | 12.1M | -11.0M | -14.8M | 4.77M | 20.8M | 5.94M | -6.93M | 7.32M | 7.00M | 521.0K |
Cap table
Built by 6ix from Initiator Pharma A/S’ releases
- Common shares
- 68,452,892
- Fully diluted
- 68,452,892
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 68,452,892 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 68,452,892 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Annette Colin | Board member · Since at least May 29, 2026 |
| Annette Säfholm | Chief Operating Business Officer (COO) · Since at least Sep 14, 2026 |
| Christina Lloyd | Board member · Since at least May 29, 2026 |
| Claus Elsborg Olesen | CEO and board member · Since at least Sep 14, 2026 |
| Gunilla Ekström | Board member · Since at least May 29, 2026 |
| Magnus Persson | Chairman of the Board · Since at least May 29, 2026 |
| Peter Holm | Board member · Since at least May 29, 2026 |
Log in to ask 6ix AI your own questions about Initiator Pharma A/S.